{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-030652","form_type":"8-K","ticker":"EDSA","cik":"0001540159","company_name":"Edesa Biotech, Inc.","filed_at":"2022-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.923801+00:00","generated_at":"2026-06-27T01:34:32.874857+00:00","sec_items":["5.02"],"event_type":"other","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Edesa Biotech grants 136,000 stock options to CEO, CFO, and President at $3.71","bullets":["Pardeep Nijhawan (CEO) granted 49,000 options; monthly vesting over 36 months, 10-year term.","Kathi Niffenegger (CFO) granted 43,500 options; Michael Brooks (President) also granted 43,500 options.","Exercise price set at $3.71 per share, equal to closing price on grant date (Feb 28, 2022).","Options vest monthly over 36 months; no immediate change in executive compensation."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-030652","json":"https://secwatch.observer/filing/0001104659-22-030652.json","markdown":"https://secwatch.observer/filing/0001104659-22-030652.md","text":"https://secwatch.observer/filing/0001104659-22-030652.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1540159/000110465922030652/0001104659-22-030652-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1540159/000110465922030652/tm228418d3_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T01:34:32.874857+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}